Show simple item record

dc.creatorSchiapparelli, Paulaes_ES
dc.creatorEnguita Germán, Mónicaes_ES
dc.creatorBalbuena, Janaes_ES
dc.creatorRey, Juan A.es_ES
dc.creatorLázcoz, Paulaes_ES
dc.creatorCastresana, Javier S.es_ES
dc.date.accessioned2019-01-22T13:34:45Z
dc.date.available2019-01-22T13:34:45Z
dc.date.issued2010
dc.identifier.issn1021-335X (Print)
dc.identifier.issn1791-2431 (Electronic)
dc.identifier.urihttps://hdl.handle.net/2454/32051
dc.description.abstractNeuroblastoma is the most common extracranial solid tumor in children, accounting for up to 10% of all childhood malignancies. Cellular heterogeneity is a hallmark of this embryonal cancer, as distinct neural crest lineages can be found within the same tumor sample. The aim of our study was to investigate the presence of a subpopulation of immature cells with features of cancer-like stem cells in 10 neuroblastoma cell lines. RT-PCR and flow cytometry were performed in order to analyze different kinds of ‘stemness genes’ such as: NESTIN (NES), CD133, SOX-2, BMI1, c-KIT, MELK1, MUSASHI-1 (MSI1), FAS, CD44 and VIMENTIN (VIM). In addition, glial and neuronal markers such as NCAM1, GFAP and B-TUBULIN III (TUBB3) were analyzed. Epigenetic changes within the CD133 (Prominin-1) gene promoter were also analyzed. Neuroblastoma cell lines showed a particular pattern of expression, suggesting the presence of an immature cancer stem cell-like subpopulation. The CD133 protein, commonly used to enrich putative cancer propagating stem cell-like populations in different kinds of solid tumors, presented a half-methylated DNA state in 7 of the 12 neuroblastoma cell lines analyzed. An increase in RNA and protein levels of CD133 was achieved following demethylation by assays using 5-aza-2'-deoxycytidine (5-Aza-dC). Since cancer stem cells are believed to be responsible for tumor metastasis, escape from anticancer therapies and disease relapse, their therapeutic targeting and analysis is crucial in neuroblastoma. Moreover, the regulation of CD133 by epigenetic changes may provide an innovative mechanism of CD133 expression as its regulation still remains unclear.en
dc.description.sponsorshipThis study was supported in part by grants from the Departmento de Salud del Gobierno de Navarra (9/07), Caja Navarra (08/13912), and Fundación Universitaria de Navarra, Pamplona; and Fondo de Investigación Sanitaria (PI081849), Madrid.en
dc.format.extent8 p.
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherSpandidos Publicationsen
dc.relation.ispartofOncology reports, 24: 1355-1362, 2010en
dc.subjectNeuroblastomaen
dc.subjectCD133en
dc.subjectEpigeneticsen
dc.subjectNeural stem cellsen
dc.titleAnalysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell linesen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeArtículo / Artikuluaes
dc.contributor.departmentUniversidad Pública de Navarra. Departamento de Ciencias de la Saludes_ES
dc.contributor.departmentNafarroako Unibertsitate Publikoa. Osasun Zientziak Sailaeu
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.rights.accessRightsAcceso abierto / Sarbide irekiaes
dc.identifier.doi10.3892/or_00000993
dc.relation.publisherversionhttps://doi.org/10.3892/or_00000993
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.type.versionVersión publicada / Argitaratu den bertsioaes
dc.contributor.funderGobierno de Navarra / Nafarroako Gobernua, 9/07es


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record